Clinical Research Directory
Browse clinical research sites, groups, and studies.
Glofitamab in Chinese Patients With R/R DLBCL
Sponsor: Peking Union Medical College Hospital
Summary
This study will evaluate the safety and efficacy of glofitamab as a single agent in Chinese patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have failed two or more lines of systemic therapy.
Official title: A Study to Evaluate Glofitamab as Single Agent in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
OBSERVATIONAL
Enrollment
20
Start Date
2024-01-01
Completion Date
2028-12-31
Last Updated
2026-03-27
Healthy Volunteers
No
Conditions
Interventions
Glofitamab
Glofitamab given in standard dosage
Locations (1)
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China